Trial
NCT00993018
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators
—
Condition
Diabetic Neuropathy
Intervention
JNJ-42160443 (1 mg)
Why stopped
Logistic reasons associated with the FDA-imposed clinical hold.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-03